000123894 001__ 123894
000123894 005__ 20240319081028.0
000123894 0247_ $$2doi$$a10.3389/fendo.2022.1082684
000123894 0248_ $$2sideral$$a132334
000123894 037__ $$aART-2022-132334
000123894 041__ $$aeng
000123894 100__ $$ade Lamas, Carmela
000123894 245__ $$aProgression of metabolic syndrome and associated cardiometabolic risk factors from prepuberty to puberty in children: The PUBMEP study
000123894 260__ $$c2022
000123894 5060_ $$aAccess copy available to the general public$$fUnrestricted
000123894 5203_ $$aIntroductionMetabolic syndrome (MetS) is a cluster of clinical and metabolic alterations related to the risk of cardiovascular diseases (CVD). Metabolic changes occurring during puberty, especially in children with overweight and obesity, can influence the risk of developing chronic diseases, especially CVD.MethodsLongitudinal study based on the follow-up until puberty of a cohort of 191 prepubertal Spanish boys and girls without congenital, chronic, or inflammatory diseases: undernutrition: or intake of any drug that could alter blood glucose, blood pressure, or lipid metabolism. The following parameters were used to determine the presence of MetS: obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL-c.ResultsA total of 75·5% of participants stayed in the same BMI category from prepuberty to puberty, whereas 6·3% increased by at least one category. The prevalence of MetS was 9·1% (prepubertal stage) and 11·9% (pubertal stage). The risk of presenting alterations in puberty for systolic blood pressure (SBP), plasma triacylglycerols, HDL cholesterol (HDL-c), and HOMA-IR was significantly higher in those participants who had the same alterations in prepuberty. MetS prevalence in puberty was predicted by sex and levels of HOMA-IR, BMI-z, and waist circumference in the prepubertal stage, in the whole sample: in puberty, the predictors were levels of HOMA-IR, BMI-z, and diastolic blood pressure in participants with obesity. Two fast-and-frugal decision trees were built to predict the risk of MetS in puberty based on prepuberty HOMA-IR (cutoff 2·5), SBP (cutoff 106 mm of Hg), and TAG (cutoff 53 mg/dl).DiscussionControlling obesity and cardiometabolic risk factors, especially HOMA-IR and blood pressure, in children during the prepubertal stage appears critical to preventing pubertal MetS effectively.
000123894 536__ $$9info:eu-repo/grantAgreement/ES/CIBERObn/CB15-00043$$9info:eu-repo/grantAgreement/ES/CIBERObn/CB15-00131$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI05-1968$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI11-01425$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI11-02042$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI11-02059$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI16-00871$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI16-01205$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI16-01301$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI20-00563$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI20-00924$$9info:eu-repo/grantAgreement/ES/ISCIII/i-PFIS-IFI17-00048$$9info:eu-repo/grantAgreement/ES/ISCIII/PI20-00988
000123894 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000123894 590__ $$a5.2$$b2022
000123894 592__ $$a1.278$$b2022
000123894 591__ $$aENDOCRINOLOGY & METABOLISM$$b36 / 144 = 0.25$$c2022$$dQ1$$eT1
000123894 593__ $$aEndocrinology, Diabetes and Metabolism$$c2022$$dQ1
000123894 594__ $$a5.6$$b2022
000123894 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000123894 700__ $$aKalén, Anton
000123894 700__ $$aAnguita-Ruiz, Augusto
000123894 700__ $$aPérez-Ferreirós, Alexandra
000123894 700__ $$aPicáns-Leis, Rosaura
000123894 700__ $$aFlores, Katherine
000123894 700__ $$0(orcid)0000-0003-0454-653X$$aMoreno, Luis A.$$uUniversidad de Zaragoza
000123894 700__ $$0(orcid)0000-0002-0902-387X$$aBueno, Gloria$$uUniversidad de Zaragoza
000123894 700__ $$aGil, Ángel
000123894 700__ $$aGil-Campos, Mercedes
000123894 700__ $$aAguilera, Concepción M.
000123894 700__ $$aLeis, Rosaura
000123894 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000123894 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000123894 773__ $$g13 (2022), [14 pp.]$$pFront. endocrinol.$$tFrontiers in Endocrinology$$x1664-2392
000123894 8564_ $$s2312610$$uhttps://zaguan.unizar.es/record/123894/files/texto_completo.pdf$$yVersión publicada
000123894 8564_ $$s2343105$$uhttps://zaguan.unizar.es/record/123894/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000123894 909CO $$ooai:zaguan.unizar.es:123894$$particulos$$pdriver
000123894 951__ $$a2024-03-18-16:59:21
000123894 980__ $$aARTICLE